Equity Research firms currently have a positive stance on shares of Stemline Therapeutics, Inc. (NASDAQ:STML). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.50. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $29.80 on a short term basis.
At the time of writing, the stock was trading at $11.31. This represents a change from the opening price of 3.28%. In terms of performance, year to date, the stock is 73.22%. The monthly stock performance comes in at 27.24%. For the quarter, shares are performing at 56.37%. Weekly performance analysis shows the equity at 6.63%.
In taking a look at technical levels, shares are trading 29.86% away from the 50 day simple moving average and 72.77% away from the 200 day simple moving average. Based on a recent bid, the stock is trading 0.17% away from it’s 52- week high and 191.49% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Stemline Therapeutics, Inc.’s RSI stands at 66.04. In looking at volatility levels, the shares saw weekly volatility of 5.16% and 6.50% over the past month.